Research and development into miniaturization, new structures, new materials and advanced packaging technologies
First written in FY2016. 23 of 36 entries say "Restated". Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「R&D expenses for the fiscal year totaled ¥277.866 billion, up 11.1% from the previous fiscal year, and represented 11.4% of consolidated net sales, up 1.1 percentage points from the previous fiscal year.」
R&D expenses increased to ¥277.866 billion, with R&D expenses as a percentage of net sales rising to 11.4%. The company is making concrete progress in the development of equipment and field productivity improvements through Epsira, advanced packaging, EUV and 3D-stacked memory. - 2026-04-30AdvancedEarnings
「Research and development expenses amounted to ¥277,866 million.」
Research and development expenses increased from ¥250,017 million in the fiscal year ended March 2025 to ¥277,866 million, indicating progress in research and development investment. - FY2026-H1AdvancedAnnual report
「R&D expenses for the six months ended the interim period totaled ¥134.827 billion, up 16.7% year on year.」
R&D expenses increased from ¥115.492 billion in the same period of the previous year to ¥134.827 billion. The company also stated that there were no material changes in the status of its R&D activities. - FY2025AdvancedAnnual report
「R&D expenses for the fiscal year totaled ¥250.017 billion, up 23.2% from the previous fiscal year, and represented 10.3% of consolidated net sales, down 0.8 percentage points from the previous fiscal year.」
Under its plan to invest more than ¥1.5 trillion in R&D over 5 years, R&D expenses for the fiscal year ending March 2025 increased to ¥250.017 billion. - FY2025-H1RestatedAnnual report
「R&D expenses for the six months ended the interim period totaled ¥115.492 billion, up 22.0% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the interim period.」
R&D expenses totaled ¥115.492 billion, up 22.0% year on year, while the company reaffirmed that there were no material changes in its R&D activities. - FY2024RaisedAnnual report
「R&D investment: More than ¥1.5 trillion (cumulative over 5 years)」
The company expanded its R&D investment plan from the previous target of more than ¥1 trillion over the 5 years beginning in the fiscal year ending March 2023 to more than ¥1.5 trillion cumulatively over the next 5 years. R&D expenses for the current fiscal year also reached a record ¥202.873 billion. - FY2024-Q2RestatedAnnual report
「R&D expenses for the six months ended the second quarter totaled ¥94.678 billion, up 3.7% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses totaled ¥94.678 billion, up 3.7% year on year, while the company reaffirmed that there were no material changes in its R&D activities. - FY2024-Q1RestatedAnnual report
「R&D expenses for the three months ended the first quarter totaled ¥43.639 billion, up 3.6% year on year. There were no material changes in the status of the Group’s R&D activities during the three months ended the first quarter.」
R&D expenses totaled ¥43.639 billion, up 3.6% year on year, reaffirming that there were no material changes in the status of its R&D activities. - FY2023RaisedAnnual report
「The company invested approximately ¥600 billion in R&D over the 5 years through the fiscal year ended March 2022. Looking ahead to future growth, it invested ¥191.1 billion in R&D in the fiscal year ending March 2023, the first year of its new medium-term management plan, and will continue proactive investment of more than ¥1 trillion over the 5 years beginning in the fiscal year ending March 2023.」
The company expanded the scale of its R&D investment from the previous plan of more than ¥400 billion over 3 years to more than ¥1 trillion over the 5 years beginning in the fiscal year ending March 2023. R&D expenses for the fiscal year ending March 2023 totaled ¥191.196 billion. - FY2023-Q3RestatedAnnual report
「R&D expenses for the nine months ended the third quarter totaled ¥137.427 billion, up 20.4% year on year. There were no material changes in the status of the Group’s R&D activities during the nine months ended the third quarter.」
R&D expenses totaled ¥137.427 billion, up 20.4% year on year, while the company explained that there were no material changes in its R&D activities. - FY2023-Q2RestatedAnnual report
「R&D expenses for the six months ended the second quarter totaled ¥91.313 billion, up 20.9% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses totaled ¥91.313 billion, up 20.9% year on year, while the company explained that there were no material changes in its R&D activities. - FY2023-Q1RestatedAnnual report
「R&D expenses for the three months ended the first quarter totaled ¥42.122 billion, up 22.6% year on year. There were no material changes in the status of the Group’s R&D activities during the three months ended the first quarter.」
R&D expenses totaled ¥42.122 billion, up 22.6% year on year, while the company explained that there were no material changes in its R&D activities. - FY2022RaisedAnnual report
「To maintain and enhance its world-leading technological innovation capabilities, the company invested ¥158.2 billion in R&D in the fiscal year ended March 2022, carrying out as planned its investment of more than ¥400 billion in R&D over 3 years announced in its medium-term management plan in May 2019. Looking ahead to future growth, the company expects R&D expenses of ¥190 billion for the fiscal year ending March 2023 and will continue to make proactive investments by leveraging its strong financial base.」
The company carried out as planned its investment of more than ¥400 billion in R&D over 3 years and increased its R&D expense forecast for the fiscal year ending March 2023 to ¥190 billion. R&D expenses for the current fiscal year reached a record ¥158.560 billion. - FY2022-Q3RestatedAnnual report
「R&D expenses for the nine months ended the third quarter totaled ¥114.096 billion, up 14.7% year on year. There were no material changes in the status of the Group’s R&D activities during the nine months ended the third quarter.」
R&D expenses totaled ¥114.096 billion, up 14.7% year on year, while the company explained that there were no material changes in its R&D activities. - FY2022-Q2RestatedAnnual report
「R&D expenses for the six months ended the second quarter totaled ¥75.547 billion, up 13.8% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses totaled ¥75.547 billion, up 13.8% year on year, while the company explained that there were no material changes in its R&D activities. - FY2022-Q1RestatedAnnual report
「R&D expenses for the three months ended the first quarter totaled ¥34.356 billion, up 14.0% year on year. There were no material changes in the status of the Group’s R&D activities during the three months ended the first quarter.」
R&D expenses totaled ¥34.356 billion, up 14.0% year on year, while the company explained that there were no material changes in its R&D activities. - FY2021AdvancedAnnual report
「To maintain and enhance its world-leading technological innovation capabilities, the company plans to invest ¥160 billion in R&D in fiscal 2022 and is proceeding as planned with its investment of approximately ¥400 billion in R&D over 3 years, as announced in its medium-term management plan.」
The company stated that it was proceeding as planned with its investment of approximately ¥400 billion in R&D over 3 years and planned to invest ¥160 billion in fiscal 2022. R&D expenses for the fiscal year reached a record ¥136.648 billion. - FY2021-Q3RestatedAnnual report
「R&D expenses for the nine months ended the third quarter totaled ¥99.475 billion, up 14.6% year on year. There were no material changes in the status of the Group’s R&D activities during the nine months ended the third quarter.」
R&D expenses totaled ¥99.475 billion, up 14.6% year on year, while the company explained that there were no material changes in its R&D activities. - FY2021-Q2RestatedAnnual report
「R&D expenses for the six months ended the second quarter totaled ¥66.377 billion, up 16.7% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses totaled ¥66.377 billion, up 16.7% year on year, while the company explained that there were no material changes in its R&D activities. - FY2021-Q1RestatedAnnual report
「R&D expenses for the three months ended the first quarter totaled ¥30.142 billion, up 17.3% year on year. There were no material changes in the status of the Group’s R&D activities during the three months ended the first quarter.」
R&D expenses totaled ¥30.142 billion, up 17.3% year on year, while the company explained that there were no material changes in its R&D activities. - FY2020AdvancedAnnual report
「As announced in its medium-term management plan, the company plans to invest approximately ¥400 billion in R&D over 3 years to maintain and enhance its world-leading technological innovation capabilities.」
The company outlined a plan to invest approximately ¥400 billion in R&D over 3 years. R&D expenses for the current fiscal year were also ¥120.268 billion, or 10.7% of net sales. - FY2020-Q3RestatedAnnual report
「R&D expenses for the nine months ended the third quarter totaled ¥86.784 billion, up 3.5% year on year. There were no material changes in the status of the Group’s R&D activities during the nine months ended the third quarter.」
R&D expenses totaled ¥86.784 billion, up 3.5% year on year, while the company explained that there were no material changes in its R&D activities. - FY2020-Q2RestatedAnnual report
「R&D expenses for the six months ended the second quarter totaled ¥56.896 billion, down 0.8% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses totaled ¥56.896 billion, while the company explained that there were no material changes in its R&D activities. - FY2020-Q1RestatedAnnual report
「R&D expenses for the three months ended the first quarter totaled ¥25.692 billion, down 1.7% year on year. There were no material changes in the status of the Group’s R&D activities during the three months ended the first quarter.」
R&D expenses for the first quarter totaled ¥25.692 billion, down 1.7% year on year, while the company explained that there were no material changes in its R&D activities. - FY2019AdvancedAnnual report
「R&D expenses for the fiscal year totaled ¥113.980 billion, up 17.4% from the previous fiscal year, and represented 8.9% of consolidated net sales, up 0.3 percentage points from the previous fiscal year.」
R&D expenses increased to ¥113.980 billion, with development progressing on next-generation devices for AI, 5G and IoT, EUV, advanced packaging and energy-saving technologies. - FY2019-Q3RestatedAnnual report
「R&D expenses for the nine months ended the third quarter totaled ¥83.889 billion, up 19.8% year on year. There were no material changes in the status of the Group’s R&D activities during the nine months ended the third quarter.」
R&D expenses totaled ¥83.889 billion, up 19.8% year on year, while the company explained that there were no material changes in its R&D activities. - FY2019-Q2RestatedAnnual report
「R&D expenses for the six months ended the second quarter totaled ¥57.338 billion, up 24.5% year on year. There were no material changes in the status of the Group’s R&D activities during the six months ended the second quarter.」
R&D expenses totaled ¥57.338 billion, up 24.5% year on year, while the company explained that there were no material changes in its R&D activities. - FY2019-Q1RestatedAnnual report
「R&D expenses for the three months ended the first quarter totaled ¥26.131 billion, up 23.3% year on year. There were no material changes in the status of the Group’s R&D activities during the three months ended the first quarter.」
R&D expenses totaled ¥26.131 billion, up 23.3% year on year, while the company explained that there were no material changes in its R&D activities. - FY2018AdvancedAnnual report
「R&D expenses for the fiscal year totaled ¥97.103 billion, up 15.9% from the previous fiscal year, and represented 8.6% of consolidated net sales, down 1.9 percentage points from the previous fiscal year.」
R&D expenses totaled ¥97.103 billion, up 15.9% year on year, with concrete progress being made in the development of next-generation devices, new memory, process integration and energy-saving technologies. - FY2018-Q3RestatedAnnual report
「R&D expenses for the nine months ended the third quarter totaled ¥70.018 billion, up 18.7% year on year. There were no material changes in the status of the Group’s R&D activities during the nine months ended the third quarter.」
R&D expenses totaled ¥70.018 billion, up 18.7% year on year, while the company explained that there were no material changes in its R&D activities. - FY2018-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter were ¥46,062 million, up 15.7% year on year. There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter.」
The company explained that research and development expenses increased 15.7% year on year, while there were no material changes in the status of its research and development activities. - FY2018-Q1RestatedAnnual report
「Total research and development expenses for the cumulative first quarter were ¥21,187 million, up 19.2% year on year. There were no material changes in the status of the Group’s research and development activities during the cumulative first quarter.」
Quarterly research and development expenses were ¥21,187 million, up 19.2% year on year, while the company explained that there were no material changes in the status of its research and development activities. - FY2017AdvancedAnnual report
「Research and development expenses for the fiscal year were ¥83,800 million, an increase of 9.8% from the previous fiscal year, and represented 10.5% of consolidated revenue, down 1.0 percentage point from the previous fiscal year. In the semiconductor manufacturing equipment business, we continue to strengthen the development of new products to address increasingly diverse manufacturing technologies.」
Research and development expenses increased to ¥83,800 million, and development is progressing in specific areas including next-generation devices, advanced packaging, new memory, and multi-patterning. - FY2017-Q3RestatedAnnual report
「Total research and development expenses for the cumulative third quarter were ¥58,977 million. There were no material changes in the status of the Group’s research and development activities during the cumulative third quarter.」
The company recorded research and development expenses of ¥58,977 million for the cumulative third quarter and stated that there were no material changes in its research and development activities. - FY2017-Q2RestatedAnnual report
「Total research and development expenses for the cumulative second quarter were ¥39,805 million. There were no material changes in the status of the Group’s research and development activities during the cumulative second quarter.」
The company recorded research and development expenses of ¥39,805 million and stated that there were no material changes in its research and development activities. - FY2016First statedAnnual report
「The Group will continue to pursue further miniaturization technologies while simultaneously advancing research and development into new structures, the introduction of new materials technologies, and new packaging technologies.」
Research and development expenses of ¥76,286 million, equivalent to 11.5% of consolidated revenue, were recorded, and development is progressing in areas including MRAM, OLED, and multi-patterning.